Digestive Diseases and Sciences

, Volume 50, Issue 12, pp 2263–2267 | Cite as

A Possible Role of GLP-1 in the Pathophysiology of Early Dumping Syndrome

  • Hiroshi YamamotoEmail author
  • Tsuyoshi Mori
  • Hiroshi Tsuchihashi
  • Hiroya Akabori
  • Hiroyuki Naito
  • Tohru Tani


Exaggerated plasma concentrations of GLP-1 precede reactive hypoglycemia after oral glucose in gastrectomy patients, resulting in late dumping syndrome. Recently, we showed that GLP-1 elicits the activation of sympathetic outflow. Because sympathetic activation is thought to be a cause of early dumping, we hypothesized that exaggerated GLP-1 may contribute to the pathophysiology of early dumping syndrome. In 11 patients after gastrectomy and 14 controls, blood pressure, heart rate, and plasma concentrations of norepinephrine, epinephrine, GLP-1, glucagon, insulin, and glucose were measured after oral glucose. In gastrectomy patients, GLP-1, norepinephrine, and heart rate peaked 15 to 30 min after oral glucose. Significant positive correlations were found among GLP-1, norepinephrine, and heart rate at 30 min, and these parameters at 30 min were significantly higher in patients with early dumping syndrome. These results suggest that GLP-1 is involved in the pathophysiology of early dumping syndrome.


dumping syndrome GLP-1 norepinephrine sympathetic insulin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Carvajal SH, Mulvihill SJ: Postgastrectomy syndromes: dumping and diarrhea. Gastroenterol Clin North Am 23:261–279, 1994PubMedGoogle Scholar
  2. 2.
    Ralphs DN, Thomson JP, Haynes S, Lawson–Smith C, Hobsley M, Le Quesne LP: The relationship between the rate of gastric emptying and the dumping syndrome. Br J Surg 65:637–641, 1978PubMedGoogle Scholar
  3. 3.
    Bloom SR, Royston CM, Thomson JP: Enteroglucagon release in the dumping syndrome. Lancet 14:789–791, 1972Google Scholar
  4. 4.
    Sagor GR, Bryant MG, Ghatei MA, Kirk RM, Bloom SR: Release of vasoactive intestinal peptide in the dumping syndrome. Br Med J 14:507–510, 1981Google Scholar
  5. 5.
    Blackburn AM, Christofides ND, Ghatei MA, Sarson DL, Ebeid FH, Ralphs DN, Bloom SR: Elevation of plasma neurotensin in the dumping syndrome. Clin Sci (Lond) 59:237–243, 1980Google Scholar
  6. 6.
    Johnson LP, Sloop RD, Jesseph JE: Treatment of “dumping” with serotonin antagonists: preliminary report. JAMA 12:493–494, 1962Google Scholar
  7. 7.
    Woodward ER, Neustein CL: The late postprandial dumping syndrome: Major Probl Clin Surg 20:28–33, 1976PubMedGoogle Scholar
  8. 8.
    Toft-Nielsen M, Madsbad S, Holst JJ: Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycemia. Diabetologia 41:1180–1186, 1998CrossRefPubMedGoogle Scholar
  9. 9.
    Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–1304, 1987PubMedGoogle Scholar
  10. 10.
    Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Drucker DJ, Elmquist JK: Central administration of glucagon-like peptide-1 receptor agonist increases blood pressure and heart rate, activates autonomic regulatory neurons. J Clin Invest 110:43–52, 2002CrossRefPubMedGoogle Scholar
  11. 11.
    Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites: J Neurosci 1:2939–2946, 2003Google Scholar
  12. 12.
    Gebhard B, Holst JJ, Biegelmayer C, Miholic J: Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome. Dig Dis Sci 46:1915–1923, 2001CrossRefPubMedGoogle Scholar
  13. 13.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 10:1183–1197, 1997Google Scholar
  14. 14.
    Sigstad H: A clinical diagnostic index in the diagnosis of the dumping syndrome. Acta Med Scand 188:479–486, 1986Google Scholar
  15. 15.
    Barragan JM, Eng J, Rodriguez R, Blazquez E: Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277:784–791, 1999Google Scholar
  16. 16.
    Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC, Bernstein IL, Seeley RJ: Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am. J Physiol 272:726–730, 1997Google Scholar
  17. 17.
    Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72, 1996CrossRefPubMedGoogle Scholar
  18. 18.
    Larsen PJ, Tang-Christensen M, Jessop DS: Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 138:4445–4455, 1997CrossRefPubMedGoogle Scholar
  19. 19.
    Mojsov S, Weir GC, Habener JF: Insulinotropic: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616–619, 1987PubMedCrossRefGoogle Scholar
  20. 20.
    Hasler WL: Dumping syndrome. Curr Treat Options Gastroenterol 5:139–145, 2002PubMedGoogle Scholar
  21. 21.
    Shemerdiak WP, Abramson EC, Schlesinger PK, Werner PL: Catecholamines in the early dumping syndrome. Clin Chem 28:722–723, 1982PubMedGoogle Scholar
  22. 22.
    Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M: Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care25:1398–1404, 2002PubMedGoogle Scholar
  23. 23.
    Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR: NN2211–1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 27:1335–1342, 2004PubMedGoogle Scholar
  24. 24.
    Welle S, Lilavivathana U, Campbell RG: Increased plasma norepinephrine concentrations and metabolic rates following glucose ingestion in man. Metabolism. 29:806–809, 1980CrossRefPubMedGoogle Scholar
  25. 25.
    Levin BE: Glucose increases rat plasma norepinephrine levels by direct action on the brain. Am J Physiol 261:1351–1357, 1991Google Scholar
  26. 26.
    Geer RJ, Richards WO, O'Dorisio TM, Woltering EO, Williams S, Rice D, Abumrad NN: Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg 212:678–687, 1990PubMedGoogle Scholar
  27. 27.
    Hasler WL, Soudah HC, Owyang C: Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 277:1359–1365, 1996PubMedGoogle Scholar
  28. 28.
    Stark A, Mentlein R: Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells. Regul Pept 15:97–102, 2002Google Scholar
  29. 29.
    Velasquez-Mieyer PA, Umpierrez GE, Lustig RH, Cashion AK, Cowan PA, Christensen M, Spencer KA, Burghen GA: Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat Metab Disor. 28:330–333, 2004Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Hiroshi Yamamoto
    • 1
    • 2
    Email author
  • Tsuyoshi Mori
    • 1
  • Hiroshi Tsuchihashi
    • 1
  • Hiroya Akabori
    • 1
  • Hiroyuki Naito
    • 1
  • Tohru Tani
    • 1
  1. 1.The Department of SurgeryShiga University of Medical ScienceShigaJapan
  2. 2.Department of SurgeryShiga University of Medical ScienceShigaJapan

Personalised recommendations